Nutriband Inc. (NASDAQ: NTRB) announced that 272,671 NTRBW warrants were exercised at a strike price of $6.43, generating approximately $1.75 million in proceeds. The warrants expired on September 30 without extension, leaving the company with no remaining tradable warrants. The proceeds are primarily intended to support the remaining clinical development of AVERSA Fentanyl and the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval.
AVERSA Fentanyl is being developed as a potential first-of-its-kind opioid patch with abuse-deterrent properties. According to a 2022 Health Advances market analysis, the product has estimated peak annual U.S. sales of $80 million to $200 million. This financing marks a critical step for Nutriband as it moves closer to seeking regulatory approval for a product that could address the growing need for safer opioid delivery systems.
The successful warrant exercise provides non-dilutive funding and simplifies the company’s capital structure by eliminating all tradable warrants. For investors, this reduces future overhang and signals confidence from warrant holders who chose to exercise at $6.43 per share. The funds will be directed toward the costly late-stage clinical trials and NDA preparation required for FDA review. If approved, AVERSA Fentanyl could become a significant player in the opioid market, offering a patch that deters abuse, misuse, diversion, and accidental exposure—a pressing public health concern.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product, AVERSA Fentanyl, incorporates the company’s proprietary AVERSA abuse-deterrent technology, which can be integrated into any transdermal patch to prevent the abuse of drugs with abuse potential. More information about Nutriband can be found at www.nutriband.com. The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB.
MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN, delivering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit MissionIR.
The implications of this funding extend beyond Nutriband. If AVERSA Fentanyl gains FDA approval, it could provide a new tool in the fight against opioid abuse, potentially reducing accidental exposure and diversion. For the pharmaceutical industry, it represents a novel approach to abuse-deterrent formulations. For patients and healthcare providers, it offers hope for a safer option in pain management. As the company advances toward an NDA submission, stakeholders will be watching closely to see if this financing accelerates the timeline and brings this innovative product to market.
